Biotech News
Related news
KNSAKiniksa2026-07-28 11:30 EST
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
XFORX4 Pharmaceuticals2026-08-06 20:15 EST
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
ARGXArgenx2026-07-16 05:00 EST
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
INMBINmune Bio2026-07-31 11:00 EST
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
KYMRKymera2026-07-28 20:01 EST
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
BNTXBioNTech2026-07-21 10:45 EST
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
REGNRegeneron Pharmaceuticals2026-06-25 20:05 EST
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
SNGXSOLIGENIX2026-08-07 11:30 EST
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results
GPCRStructure Therapeutics2026-08-06 20:05 EST
Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
AVTXAvalo Therapeutics2026-08-06 11:00 EST
Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates
Kiniksa
IL-1 Cardiovascular Franchise Kiniksa Pharmaceuticals develops and commercializes therapies for diseases with strong biological rationale, with an emphasis on cardiovascular inflammation. Its portfolio is centered on blocking interleukin-1 alpha and beta signaling. ARCALYST ARCALYST, or rilonacept, is a weekly subcutaneous IL-1 cytokine...
Recent company news
KNSAKiniksa2026-08-07 20:01 EST
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
KNSAKiniksa2026-07-28 11:30 EST
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
KNSAKiniksa2026-07-23 20:01 EST
Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026
KNSAKiniksa2026-05-29 20:01 EST
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
KNSAKiniksa2026-04-28 11:30 EST
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
Stock data
- Close
- 76.51 USD
- Market cap
- 3.61B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States